Market Structure: Old Leadership Fades as Rotation Holds — July 28, 2026
Broad sector participation is absorbing technology weakness, but narrow stock-level breadth keeps the market constructive and selective.
CAMS Research Desk
SPCX Research Note — Earnings Meets Supply
SpaceX operating progress meets SPCX’s unresolved post-IPO tape as first earnings and a large August share release test public-market demand.
SPCX Deep Coverage Review — Analysis as of July 27, 2026
SpaceX has rare operating assets, but its first public report and an unprecedented share release leave SPCX sponsorship and valuation unresolved.
WST Research Note — Growth Meets a Credibility Test
West Pharmaceutical’s strong quarter meets a harder test from valuation, market structure and unresolved oral-drug substitution risk.
WST Deep Coverage Review — Analysis as of July 27, 2026
West Pharmaceutical’s beat-and-raise supports the recovery thesis, but a heavy-volume reversal and oral-drug substitution risk keep confirmation incomplete.
MOH Research Note — The Beat Masks Strain
Molina’s earnings beat and raised outlook face a harder test from weak premium revenue, declining membership and sharply compressed margins.
MOH Deep Coverage Review — Analysis as of July 27, 2026
Molina’s earnings beat masks weaker premium revenue, declining membership and compressed margins while the shares lag a strong health-care tape.
Desk Note — NVIDIA’s $5B SSI Bet · Jul 27
NVIDIA’s $5 billion SSI investment supports Vera Rubin demand while raising capital-allocation and customer-independence questions.
ASML Research Note — Monopoly Quality Needs Confirmation
ASML’s monopoly remains intact, but bookings evidence and China-policy exposure must confirm the next phase of the equipment cycle.
ASML Deep Coverage Review — Analysis as of July 27, 2026
ASML’s monopoly and margins remain formidable, but bookings gaps and China-policy uncertainty leave the near-term cycle unconfirmed.